Biomarin Pharmaceutical Company Leadership

Biomarin Pharmaceutical Management Team Effectiveness

The company has return on total asset (ROA) of 0.0615 % which means that it generated a profit of $0.0615 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0907 %, meaning that it created $0.0907 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 15th of February 2026, Return On Tangible Assets is likely to grow to 0.06. Also, Return On Capital Employed is likely to grow to 0.07. At this time, Biomarin Pharmaceutical's Net Tangible Assets are very stable compared to the past year. As of the 15th of February 2026, Return On Tangible Assets is likely to grow to 0.06, while Intangible Assets are likely to drop about 243.9 M. As of the 15th of February 2026, Net Income Applicable To Common Shares is likely to grow to about 170.9 M, while Common Stock Shares Outstanding is likely to drop about 133.8 M. Biomarin Pharmaceutical holds a total of 192.11 Million outstanding shares. The majority of Biomarin Pharmaceutical outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biomarin Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biomarin Pharmaceutical. Please pay attention to any change in the institutional holdings of Biomarin Pharmaceutical as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Biomarin Pharmaceutical in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Biomarin Pharmaceutical, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Biomarin Pharmaceutical Workforce Comparison

Biomarin Pharmaceutical Profit Margins

The company has Profit Margin (PM) of 0.17 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.06.

Biomarin Pharmaceutical Insider Trading History

Biomarin Pharmaceutical Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Biomarin Pharmaceutical often depends on how effective the management is. Biomarin Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biomarin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biomarin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Understanding Biomarin Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biomarin's accounting equity. The concept of intrinsic value - what Biomarin Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biomarin Pharmaceutical's price substantially above or below its fundamental value.

It's important to distinguish between Biomarin Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomarin Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biomarin Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.